Ovagen

Also known as: EDL, Glu-Asp-Leu, T-35

Evidence: Preclinical

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

Overview

Khavinson-series synthetic tripeptide (EDL); despite the name, its published work is on kidney: it protected rat kidneys in toxic and ischemic injury models.

Ovagen is a synthetic tripeptide (EDL, Glu-Asp-Leu) from the St. Petersburg Institute of Bioregulation and Gerontology. It is not an ovarian peptide. The developer lists it as a nephroprotector and a hepatoprotector; the hepatoprotector label cites a patent application, not a study (Khavinson 2022). The published work is renal: EDL prevented oliguria and azotemia and cut proteinuria in rats with gentamicin nephropathy and kidney ischemia-reperfusion (Zamorskii 2017) and normalized kidney function in cisplatin-induced acute renal failure (Zamorskii 2015). In aging renal cell cultures it acted on MMP-14 (Khavinson 2014). No human trial has been published.

Benefits

Kidney protection in gentamicin, cisplatin and ischemia-reperfusion injury models (rat), renal cell aging markers (in vitro)

Dosing reference

Research dose: 200 to 1000 mcg daily: vendor/community range, no published human dose
Range: 200 to 1000 mcg, 1x daily

Sold as oral capsules and as lyophilized powder for injection; vial size (20 mg) is not a dose. No published abstract states a dose in any species. Community protocols run 10 to 20 day courses two or three times a year; no study compared schedules.

Mechanism

Proposed. In rat kidney injury models EDL prevented the fall in antioxidant enzyme activity, suppressed lipid peroxidation and normalized energy supply to kidney cells (Zamorskii 2017). In aging primary kidney cell cultures it acted on the gelatinase MMP-14 (Khavinson 2014). The developer's review lists DNA binding among its effects (Khavinson 2021). The old text, which described follicle and estrogen regulation in ovarian cells, has no published source.

Evidence

Preclinical: animal or in vitro data only

Prevented oliguria and azotemia, lowered proteinuria and preserved antioxidant enzymes in rats with gentamicin nephropathy and kidney ischemia-reperfusion (Zamorskii et al., 2017)
Normalized diuresis, creatinine excretion and glomerular filtration in rats with cisplatin-induced acute renal failure (Zamorskii et al., 2015)
Acted on MMP-14 in primary kidney cell cultures during in vitro aging (Khavinson et al., 2014)
The developer's 2021 systematic review lists EDL (Ovagen) for renal function and hepatoprotection (Khavinson et al., 2021)
Human-trial status: no published human study; no study on ovarian or reproductive tissue exists

References

Side effects

No controlled safety study has been published in any species, and the animal and cell studies, almost all from the developing institute, were not designed to detect harm. The rat kidney studies report no nephrotoxicity (Zamorskii 2017). Commonly reported (anecdotal): injection-site irritation with injectable forms; oral capsules draw few complaints.

Storage

Storage: Room temperature
Lyophilized: 24+ months

Pharmacology

Half-life: No published pharmacokinetic data in any species
Bioavailability: Not measured in any species
Molecular weight: 375.37 Da
Sequence: EDL (Glu-Asp-Leu)